Rahul Bhansali

Dr. Rahul Bhansali

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
MSMelinda E. Snitow
Melinda E. Snitow
RBRahul Bhansali
Rahul Bhansali
PKPeter S. Klein
Peter S. Klein
Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar disorder. The known molecular targets of lithium are surprisingly few and include the signaling kinase glycogen synthase kinase-3 (GSK-3), a group of structurally related phosphomonoesterases that includes inositol monophosphatases, and phosphoglucomutase. Here we present a brief history of the therapeutic uses of lithium and then focus on GSK-3 as a therapeutic target in diverse diseases, including bipolar disorder, cancer, and coronavirus infections.

25 May 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BTBenjamin J. Thompson
Benjamin J. Thompson
RBRahul Bhansali
Rahul Bhansali
LDLauren Diebold
Lauren Diebold
DCDaniel E. Cook
Daniel E. Cook
LSLindsay Stolzenburg
Lindsay Stolzenburg
JCJohn D. Crispino
John D. Crispino
Pre–B and pre–T lymphocytes must orchestrate a transition from a highly proliferative state to a quiescent one during development. Cyclin D3 is essential for these cells’ proliferation, but little is known about its posttranslational regulation at this stage. Here, we show that the dual specificity tyrosine-regulated kinase 1A (DYRK1A) restrains Cyclin D3 protein levels by phosphorylating T283 to induce its degradation. Loss of DYRK1A activity, via genetic inactivation or pharmacologic inhibition in mice, caused accumulation of Cyclin D3 protein, incomplete repression of E2F-mediated gene transcription, and failure to properly couple cell cycle exit with differentiation. Expression of a nonphosphorylatable Cyclin D3 T283A mutant recapitulated these defects, whereas inhibition of Cyclin D:CDK4/6 mitigated the effects of DYRK1A inhibition or loss. These data uncover a previously unknown role for DYRK1A in lymphopoiesis, and demonstrate how Cyclin D3 protein stability is negatively regulated during exit from the proliferative phases of B and T cell development.

10 June 2016 in Leukemia
Verified
Journal Article
Closed access
PDF file
PLP Lee
P Lee
RBRahul Bhansali
Rahul Bhansali
SIS Izraeli
S Izraeli
NHN Hijiya
N Hijiya
JCJ D Crispino
J D Crispino

26 February 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
MRMalini Rammohan
Malini Rammohan
EHEthan Harris
Ethan Harris
RBRahul Bhansali
Rahul Bhansali
EZEmily Zhao
Emily Zhao
LLLoretta S. Li
Loretta S. Li
JCJohn D. Crispino
John D. Crispino

14 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
JZJoanna Zurko
Joanna Zurko
INImran Nizamuddin
Imran Nizamuddin
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
KDKevin David
Kevin David
Jonathon B. CohenJonathon B. Cohen
Jonathon B. Cohen
RKReem Karmali
Reem Karmali
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory aggressive B-NHL; however, it remains unclear how to sequence these therapies pre– and post–CAR-T. We conducted a multicenter retrospective analysis to describe peri–CAR-T practice patterns and survival predictors for patients receiving CD19-directed CAR-T. Patients (n = 514) from 13 centers treated with CAR-T for B-NHL between 2015-2021 were included in the study. Survival curves were constructed using Kaplan-Meier method. Multivariate Cox regression analysis was used to determine the impact of the variables on survival outcomes. For all patients receiving CAR-T, a greater number of lines of therapy pre-CAR-T apheresis and bridging therapy were predictive of inferior progression-free survival (PFS) and overall survival (OS). The median PFS and OS from the time of CAR-T cell infusion were 7.6 and 25.6 months, respectively. From the time of progression post–CAR-T, the median OS was 5.5 months. The median PFS of treatments administered in the first-line post–CAR-T failure was 2.8 months. Patients with refractory disease on day 30 had inferior OS and were less likely to receive subsequent treatment(s) than other patients with CAR-T failure. Allogeneic hematopoietic cell transplantation for selected patients at any time following CAR-T failure led to durable responses in over half of patients at 1 year. These data provide a benchmark for future clinical trials in patients with post–CAR-T cell progression, which remains an unmet clinical need.

28 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
RKReem Karmali
Reem Karmali
RMRushad Machhi
Rushad Machhi
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
GSGeoffrey Shouse
Geoffrey Shouse
Jason T. RomancikJason T. Romancik
Jason T. Romancik
LGLeo Gordon
Leo Gordon
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of the convergence of race and social determinants of health on outcomes for patients treated with CAR-T therapy. We examined the impact of interactions between race and insurance type on health care use and outcomes in patients treated with CAR-T therapy for aggressive B-NHL. Adult patients with r/r B-NHL treated with CD19 CAR-Ts were identified between 2015 and 2021 across 13 US academic centers. Insurance type, demographic, and clinical data were collected and analyzed. In total, 466 adult patients were included in our analysis. Median follow-up after CAR-T therapy was 12.7 months. Median progression-free survival (mPFS) was longer for Caucasians (11.5 months) than for African Americans (3.5 months; hazard ratio [HR], 1.56 [1.03-2.4]; P = .04) or Asians (2.7 months; HR, 1.7 [1.02-2.67]; P = .04). Differences in median overall survival (mOS) were not significant. For Medicare (n = 206) vs Medicaid (n = 33) vs private insurance (n = 219) vs self-pay (n = 7): mPFS was 15.9 vs 4.2 vs 6.0 vs 0.9 months (P < .001), respectively; and mOS was 31.2 vs 12.8 vs 21.5 vs 3.2 months (P < .001), respectively. Our multicenter retrospective analysis showed that race and insurance status can affect outcomes for patients treated with CAR-T therapy.